Abstract:A DMAP catalyzedsynthesis of new 4-benzyloxy-and 4-aryloxy-2-trichloromethylquinazolines was studied, in a view to react 4-chloroquinazolines with poorly nucleophilic alcohols such as benzylic alcohols, via a simple and cheapS N Ar reaction approach. A fast (1 h) general operating procedure, affording good reaction yields,was achieved under microwave irradiation. Thus, a series of 35 molecules was obtained and evaluated in vitro on the K1 multi-resistant P. falciparum strain, in parallel with a cytotoxicity assessment on the human HepG2 cell line. 5 hit-molecules were identified, presenting both promising antiplasmodial activity (1.5 µM < IC 50 < 2 µM) and low cytotoxicities (25 µM < CC 50 < 45 µM). Apart for 2 molecules, the global series displayed a satisfying solubility in the aqueous biological media. Structure-activity relationships showed that the molecules presenting a benzyloxy moiety were less cytotoxic than the ones bearing a phenoxy moiety at position 4 of the quinazoline ring. It also appeared that the introduction of a heteroaryl moiety afforded inactive compounds. Finally, the most active and selective molecules (Selectivity index = 22-27) were the ones presenting either an unsubstituted benzyloxy group or a phenoxy group, this last bearing a p-bromo or an o-acetyl substituent.
Looking for new antiplasmodial quinazolines: DMAP-catalyzed synthesis of4-benzyloxy-and 4-aryloxy-2-trichloromethylquinazolines and their in vitro evaluation toward Plasmodium falciparum

Introduction
Plasmodium falciparum is the protozoa responsible for cerebral malaria, the leading cause of death among parasitic infections worldwide. According to the 2015 World Malaria Report [1] , 214 million people were infected byPlasmodium in 2014. It was also estimated that 438.000 people died from this parasitic infection, mainly because of the cerebral form of the disease. About 88% of the estimated deaths occurred in Africa, children under five representing a large majority of the victims.
Since the beginning of 2000, a very significant improvement of the situation has been reached, thanks to the WHO intervention and the involvement of several non-governmental organizations (Bill and Melinda Gates Foundation, Roll Back Malaria, Medicines for Malaria Venture…). Nevertheless, the emergence of drug-resistant strains of the parasite in Africa, South-East Asia and South America remains a serious concern for the medical and scientific community, in a view to keep on controlling the infection and to try to eradicate the disease. For that purpose, the treatment of the patients infected by P. falciparum is based on combination therapies including artemisinin derivatives, in order to cure the disease and avoid the selection or resistant strains and their spreading in the exposed population, which would lead to a very worrying sanitary situation. Concerning artemisinin derivatives, which are nowadays keymolecules for the treatment ofP. falciparum malaria, resistances are emerging in Asia [2] , and it has been demonstrated that they areresponsible for therapeutic failures in several infected patients [3] . Moreover, it has also recently been highlighted that the African Anopheles gambiae mosquito could transmit such Asian resistant parasites [4] , indicating a major worldwide spreading risk. Thus, research efforts have to be maintained so as to discover new chemical entities presenting novel antiplasmodial mechanisms of action, to use in combination therapies with the existing antimalarial drugs, to guaranty their durable efficiency. Considering all the scaffolds which were studied for their antiplasmodial potential, several bioactive molecules are based on a quinazolinering. For example, febrifugine is natural alkaloidincluding a quinazolinone moiety which isextracted from the Chinese herb Dichroafebrifuga, and which was employed by local people as a medicine against fevers caused by malaria. Some synthetic febrifugine derivatives were prepared and displayed good in vitro and in vivo potential [5] . Many other quinazoline derivatives were synthesized and evaluated toward P. falciparum, in particular, quinazolines bearing, an amino group [6] , an alkylamine moiety [7, 8] or an anilino substituent [9] [10] [11] at position 4 of the quinazoline ring.
In continuation with our research activity focusing on the synthesis of new nitrogencontaining heterocycles with anti-infective potential [12] [13] [14] , our research group previously reported the synthesis and in vitro study ofnumerous antiplasmodial molecules based on a 2-trichloromethylquinazoline scaffold. Thus, several series bearing ananilino [10] , aryl [15] , thiophenol [16] , sulfonamide [17] or alkynyl moiety [18] at position 4 of the quinazoline ring were prepared and revealed several hit-molecules which are presented in Table 1 . Among the antiplasmodial hit-molecules which were identified, a 4-phenoxy-2-trichloromethylquinazoline derivative was also discovered [19] , presenting a 50% inhibitory concentration (IC 50 ) of 1.1 µM and a 50% cytotoxicity concentration (CC 50 ) of 50 µM (Table   1) , reaching an encouraging selectivity index of 45, in comparison with chloroquine and doxycycline. Then, searching for novel analogs presenting an oxygen-containing substituent at position 4 of the quinazoline ring, we present herein the synthesis work which was conducted for reacting 4-chloro-2-trichloromethylquinazoline with poorly nucleophilic benzylic alcohols, to afford the target molecules in a fast, simple and cheap way, using the S N Ar reaction. The in vitro biological evaluation and the SARs will then be presented and discussed. 
Results and discussion
Synthesis
As aliphatic alcohols display poor nucleophilicity, reacting them with chlorinated azaheterocycles, to provide the corresponding S N Ar products, is difficult and usually requires the preliminary in situ formation of the correspondingalcoholate anion. Thus, in quinazoline series, various operating procedures were reported in the literature, using methylate sodium in methanol [20] , sodium hydride in dry DMF [21] , sodium hydride in dry THF [22, 23] or sodium in dry THF [24] . These protocols, leading to the expected products in moderate to good yields (32-84%), present several disadvantages as they consist in 2 step-reactions (formation of the anion followed by the S N Ar), require the use of perfectly dry organic solvents and involve highly reactive and flammable reagents. Moreover, we tried to react 4-chloro-2-trichloromethylquinazolinewith benzyl alcohol, using the reaction conditions we previously reported for the synthesis of 4-phenoxyquinazolines [19] (NaH, DMSO, RT, 24 h) and obtained the expected product in a very low 11% yield (Table 2, entry 13). Among the available alternative strategies, palladium cross-coupling reactions could have been considered. Nevertheless, because of the expensive costs of both palladium catalysts and ligands, in order to set up a cheap and simple operating procedure, we decided to study the one pot S N Ar reaction between 4-chloro-2-trichloromethylquinazoline 1and benzyl alcohol. To facilitate the S N Ar reaction between 1 and poorly nucleophilic species like amino- substituted heterocycles, our group recently reported a synthetic procedure usingN-Ndimethylaminopyridine (DMAP) as an efficient catalyst, involving the formation of a highly reactive quinazoline intermediate which we isolated and characterized by X-ray diffraction [25] . Then, benefiting from our experience in the use of microwave irradiation for introducing substituents at position 4 of the quinazoline ring [26] , and considering that a successful microwave-assisted S N Ar reaction between a 4-chloroquinazoline derivative and ethylene glycol had been reported [27] , we focused on a S N Ar reaction protocol combining a DMAP catalysis with microwave irradiation.For that purpose, we first prepared substrate 1 (Figure 1 ), from commercial 2-methylquinazolin-4(3H)-one, according to a previously reported microwave synthesis using PCl 5 in POCl 3 [28] . Then, the DMAP-catalyzed S N Ar reaction between 1 and benzyl alcohol was studied ( Figure  2 ) by varying the solvent nature, the amount of catalyst, the amount of benzyl alcohol, the reaction temperature, the microwave irradiation mode and the reaction time. The experimental results are presented in Table 2 . When using DMAP in the presence of toluene, the reaction yield reached 23%, higher than with DMSO, DMF, or THF. Then, by increasing the amount of DMAP to 0.2 equiv., the reaction yield was improved to 42%. Finally, via a 1 h monomode microwave irradiation at 130°C, the use of 0.3 equiv. of DMAP, allowed a decrease in the amount of alcohol (1,2 equiv.) needed and a53% reaction yield was reached. From that point, decreasing reaction temperature, reaction time, or using a multimode microwave irradiation did not provide satisfying reaction yields. For comparison purposes, the same reaction was carried out without DMAP and then conducted with other tertiary amine derivatives (DBU, DABCO and TEA). As shown in Table 3 , under these reaction conditions, the presence ofDMAP appears mandatory for the reaction to proceed. Moreover, among tertiary amines, only DMAP allowed the synthesis of 2, considering that substrate 1 was found unconsumed after reaction in the conditions of entries 3 and 4 (only 5% conversion with TEA). According to this general procedure, summarized in Figure 3 , the S N Ar reaction of 1 with aliphatic alcohols (mainly benzyl alcohols) was then extended to the synthesis of a series of 18 derivatives (molecules 2-19). As presented in Table 4 , the reaction yields varied from moderate (35%) to excellent 97%. In addition, the same protocol was applied to the synthesis of a series of 13 derivatives bearing a phenoxy moiety at position 4 of the quinazoline ring (molecules 20-32). These molecules were obtained in 38-99% yields. Finally, 4 more derivatives were prepared, bearing a heteroaryloxy moiety at position 4 of the quinazoline ring (molecules 33-36), in 55-98% yields. Thus, this DMAP-catalyzed operating procedure appeared as generally applicable to aliphatic alcohols, phenols and hydroxyheteroaryl reagents. Among the 35 synthesized molecules, 2 were previously reported. Thus, compound 2 was mentioned in a 2001 publication [29] but no experimental data is available about it up to day. Concerning quinazoline27, it is to note that it had previously been synthesized, according to another protocol [19] , in 25% yield. As shown in Figure 4 , from the same substrate, the presently described DMAP protocol led to the formation of product27 in 98% yield and only 1 h, indicating its high efficiency for preparing most of 4-phenoxyquinazolines (apart for molecules 23 and 26).
Figure 4.
Comparison of synthetic routes A and B [19] for the synthesis of compound 27
Biological evaluation
All synthesized molecules were then evaluated in vitro on the multi-resistant K1 P. falciparum strain, by determining their 50% inhibitory concentration (IC 50 ), and compared with 2 antimalarial drug-compounds: chloroquine and doxycycline. In parallel, these molecules were assessed in vitro on the HepG2 human hepatocyte cell line, by determining their 50% cytotoxic concentrations (CC 50 ) and comparing them to the one of doxorubicin, used as a cytotoxic reference drug-compound, in order to calculate their respective selectivity index (SI = CC 50 /IC 50 ). The results are presented in Table 5 and highlight 5 hit-molecules (2, 6, 16, 20, 26), presenting both IC 50 values < 2 µM and CC 50 values > 25 µM, reaching selectivity indexes ranging between 17 and 27. 
Structure-activity relationships
Apart compounds 8 and 23, all tested molecules presented satisfying solubilities in the biological media as the determination of their in vitro activities was not hindered by any precipitation. In the benzyloxy series, no cytotoxicity was identified whereas, in the phenoxy series, compounds 25, 27 and 31, presenting a substituent at the meta position of the benzene ring, displayed low CC 50 values (0.5-5 µM). In the heteroaryloxy series, compound 34 also appeared slightly cytotoxic (CC 50 = 5 µM), because of the presence of two bromine atoms. Concerning antiplasmodial activity, the molecules belonging to the heteroaryloxy series were not active. In the benzyloxy series, compounds 2, 6 and 16 appeared as hit-molecules with IC 50 values ranging from 1.5 to 2 µM and selectivity indexes being around 20, in comparison with the values noted for reference drugs.Compound 2, bearing a benzyloxy group at position 4 of the quinazoline ring, was found more active and selective than its phenyloxy analog (CI 50 = 3,1 µM / SI = 16) [19] . In most cases (apart for nitrated molecule 6), the substitution of the benzene ring of the benzyloxy group was globally deleterious toward antiplasmodial activity, nevertheless, considering compound 16, it can be noted that the introduction of a substituent on the benzylic carbon, for example via a nitrile function, is compatible with maintaining biological activity.
In the phenoxy series, compounds 20 and 26 were identified as hit-molecules, displaying IC 50 values of 1.8 and 1.5 µM and selectivity indexes above 25. When comparing para-brominated molecule 20 to its chlorinated analog (Table 1 ), in accordance with the SAR conclusions that we previously reported [19] , it can be concluded that the substitution of the benzene ring by a chlorine or bromine atom is favorable toward the antiplasmodial activity if located at the para position of the benzene ring, chlorine remaining slightly more favorable. Indeed, we also identified that the introduction of an acetyl substituent at the ortho position of the benzene ring (compound 26) allowed antiplasmodial activity. Thisselective activity is decreased when changing the substitution position or when changing the acetyl group into a formyl analog (compound 28). To validate the key role played by the 2-trichloromethylquinazoline scaffold of hit-molecule 26, its dehalogenated analog 37 was prepared in two steps ( Figure 5 ).
Figure 5. Two step synthesis of molecule 37
As presented in Figure 6 , the antiplasmodial activity of compound 26 depends from the presence of a trichloromethyl group at position 2 of the quinazoline ring, in accordance with the results that we previously reported. Thus, compounds 2 (in the original benzyloxy series) and 26 (first active o-substituted phenoxy derivative) appear as novel hit-molecules and extend the available SAR data in the 2-trichloromethylquinazoline series. 2-Methylquinazolin-4(3H)-one was purchased from Sigma Aldrich.
4-Chloro-2-trichloromethylquinazoline(1)
4-Chloro-2-trichloromethylquinazoline 1 was prepared as described in the literature [28] . 
4-(3-Nitrobenzyloxy)-2-(trichloromethyl)quinazoline (7)
Yield 91%. 
2-(Trichloromethyl)-4-(4-(trifluoromethyl)benzyloxy)quinazoline (9)
Yield 83%. 
4-(4-Isopropylbenzyloxy)-2-(trichloromethyl)quinazoline (10)
Yield 81%. Pale beige powder. Mp121 °C, (isopropanol 
3.1.13.4-(3,4-Dimethoxybenzyloxy)-2-(trichloromethyl)quinazoline (11)
Yield 64%. Beige powder. Mp127 °C, (isopropanol 
3.1.14.4-(1-Phenylethoxy)-2-(trichloromethyl)quinazoline (12)
Yield 35%. Beige powder. Mp141 °C, (isopropanol 
4-(1-(2,4-Dichlorophenyl)ethoxy)-2-(trichloromethyl)quinazoline (14)
Yield 69%. Brown powder. Mp123 °C, (isopropanol 
4-(1-Phenylprop-2-ynyloxy)-2-(trichloromethyl)quinazoline (15)
Yield 84%. Pale yellow powder. Mp 120 °C, (isopropanol 
3.1.20.(E)-4-(3-(4-Nitrophenyl)allyloxy)-2-(trichloromethyl)quinazoline (18)
Yield 45%. 
4-(3-(Benzyloxy)benzyloxy)-2-(trichloromethyl)quinazoline (19)
Yield 68%. Yellow powder. Mp 96 °C, (isopropanol). 
4-(4-Bromophenoxy)-2-(trichloromethyl)quinazoline (20)
4-(2-Bromophenoxy)-2-(trichloromethyl)quinazoline (22)
Yield 99%. White powder. Mp 138 °C, (isopropanol). 
Preparation of 1-(2-(2-methylquinazolin-4-yloxy)phenyl)ethanone (37)
Molecule 37 was prepared in two steps from commercial 2-methylquinazolin-4(3H)-one. This last was first chlorinated at position 4, by using POCl 3 , according to a previously microwaveassisted reported procedure [25] , leading to 4-chloro-2-methylquinazoline in 73% yield. Then, the general DMAP-catalyzed operating procedure described in § 3. 
Biology
In vitroAntiplasmodial evaluation
In this study, a K1 culture-adapted P. falciparum strain resistant to chloroquine, pyrimethamine and proguanil was used in an in vitro culture. Maintenance in continuous culture was done as described previously by Trager and Jensen [30] . Cultures were maintained in fresh A+ human erythrocytes at 2.5% hematocrit in complete medium (RPMI 1640 with 25 mM HEPES, 25 mM NaHCO 3 , 10% of A+ human serum) at 37 °C under reduced O 2 atmosphere (gas mixture 14% O 2 , 6% CO 2 , and 80% N 2 ). Parasitaemia was maintained daily between 1% and 6%. The P. falciparum drug susceptibility test was carried 
In vitro Cytotoxicity evaluation
HepG2 cell line was maintained at 37 °C, 6% CO 2 , 14% O 2 , 80% N 2 , with 90% humidity in RPMI supplemented with 10% foetal bovine serum, 1% L-glutamine (200 mM) and penicillin (100 U/mL) / streptomycin (100 µg/mL) (complete RPMI medium). The evaluation of the 
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